Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (61-70 of 286) with videos related to

Pageof 29
Sort By:
Thoracic Cancer|May 15, 2026
Impact of Anti-Inflammatory Drug Therapy on the Efficacy of First-Line Atezolizumab Treatment in Patients With Advanced Non-Small Cell Lung Cancer: An Integrated Analysis of Five Randomized Controlled TrialsKazuki Takada, Alessio Cortellini, Shinkichi Takamori, et al.
Oncology Reports|May 23, 2012
Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusionFrancesco A Mauri, David J Pinato, Pritesh Trivedi, et al.
Lung Cancer (Amsterdam, Netherlands)|October 17, 2025
Probiotic supplement exposure and outcomes of patients with non-small cell lung cancer treated with first-line atezolizumab therapy: Pooled analysis of individual patient data from five randomized control trialsKazuki Takada, Mototsugu Shimokawa, Alessio Cortellini, et al.
Hepatology (Baltimore, Md.)|November 2, 2018
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaMichael J Flynn, Anwar A Sayed, Rohini Sharma, et al.
Journal of Clinical Pathology|March 9, 2016
Gene of the month: AxlMatthew Brown, James R M Black, Rohini Sharma, et al.
JHEP Reports : Innovation in Hepatology|April 19, 2026
Scientific, regulatory, and practical considerations for bringing hepatocellular carcinoma biomarkers into clinical practiceBlanca Botía Martínez-Artero, Eleonora Alimenti, James K Carter, et al.
Lancet (London, England)|July 27, 2023
The price and value of therapeutic synergy in liver cancerDavid J Pinato, Antonio D'Alessio, Ciro Celsa, et al.
Hepatology Communications|June 3, 2024
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the futureAmit G Singal, Mark Yarchoan, Adam Yopp, et al.
Future Oncology (London, England)|September 16, 2024
Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL)Alessandro Troiani, Maria Martinez, Caroline Ward, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2025
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular CancerDavid J Pinato, Pasquale Lombardi, Antonio D'Alessio, et al.
Pageof 29

Showing results (61-70 of 286) with videos related to

Sort By:
Pageof 29
Thoracic Cancer|May 15, 2026
Impact of Anti-Inflammatory Drug Therapy on the Efficacy of First-Line Atezolizumab Treatment in Patients With Advanced Non-Small Cell Lung Cancer: An Integrated Analysis of Five Randomized Controlled TrialsKazuki Takada, Alessio Cortellini, Shinkichi Takamori, et al.
Oncology Reports|May 23, 2012
Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusionFrancesco A Mauri, David J Pinato, Pritesh Trivedi, et al.
Lung Cancer (Amsterdam, Netherlands)|October 17, 2025
Probiotic supplement exposure and outcomes of patients with non-small cell lung cancer treated with first-line atezolizumab therapy: Pooled analysis of individual patient data from five randomized control trialsKazuki Takada, Mototsugu Shimokawa, Alessio Cortellini, et al.
Hepatology (Baltimore, Md.)|November 2, 2018
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaMichael J Flynn, Anwar A Sayed, Rohini Sharma, et al.
Journal of Clinical Pathology|March 9, 2016
Gene of the month: AxlMatthew Brown, James R M Black, Rohini Sharma, et al.
JHEP Reports : Innovation in Hepatology|April 19, 2026
Scientific, regulatory, and practical considerations for bringing hepatocellular carcinoma biomarkers into clinical practiceBlanca Botía Martínez-Artero, Eleonora Alimenti, James K Carter, et al.
Lancet (London, England)|July 27, 2023
The price and value of therapeutic synergy in liver cancerDavid J Pinato, Antonio D'Alessio, Ciro Celsa, et al.
Hepatology Communications|June 3, 2024
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the futureAmit G Singal, Mark Yarchoan, Adam Yopp, et al.
Future Oncology (London, England)|September 16, 2024
Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL)Alessandro Troiani, Maria Martinez, Caroline Ward, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2025
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular CancerDavid J Pinato, Pasquale Lombardi, Antonio D'Alessio, et al.
Pageof 29